Related references
Note: Only part of the references are listed.Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα
Chiara Borsari et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)
Occurrence of Morpholine in Central Nervous System Drug Discovery
Elena Lenci et al.
ACS CHEMICAL NEUROSCIENCE (2021)
Targeting Phosphoinositide 3-Kinase-Five Decades of Chemical Space Exploration
Chiara Borsari et al.
CHIMIA (2021)
Chemical and Structural Strategies to Selectively Target mTOR Kinase
Chiara Borsari et al.
CHEMMEDCHEM (2021)
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability
Chiara Borsari et al.
RSC MEDICINAL CHEMISTRY (2021)
Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules
Angeliki P. Kourounakis et al.
MEDICINAL RESEARCH REVIEWS (2020)
Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR)
Archana Kumari et al.
BIOORGANIC CHEMISTRY (2020)
Morpholine As a Scaffold in Medicinal Chemistry: An Update on Synthetic Strategies
Ariadni Tzara et al.
CHEMMEDCHEM (2020)
Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase
Gregory S. Basarab et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex
Wiebke Theilmann et al.
NEUROPHARMACOLOGY (2020)
4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders
Chiara Borsari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Revealing quinquennial anticancer journey of morpholine: A SAR based review
Fatima Arshad et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase
Denise Rageot et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor
Chiara Borsari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety
Chiara Borsari et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
Claudia Brandt et al.
NEUROPHARMACOLOGY (2018)
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-y1})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders
Denise Rageot et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
Florent Beaufils et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
Thomas Bohnacker et al.
NATURE COMMUNICATIONS (2017)
Morita-Baylis-Hillman Approach toward Formal Total Synthesis of Tamiflu and Total Synthesis of Gabaculine
Subhendu Bhowmik et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2013)
Medicinal Chemistry of 2,2,4-Substituted Morpholines
E. A. Rekka et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition
Brian S. Safina et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Ring opening of cyclic sulfamidates with bromophenyl metal reagents: complementarity of sulfamidates and aziridines
Paul Hebeisen et al.
TETRAHEDRON LETTERS (2011)
Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors
Arie Zask et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Levofloxacin - A review of its use as a high-dose, short-course treatment for bacterial infection
Vanessa R. Anderson et al.
DRUGS (2008)
Bimorpholine-mediated enantioselective intramolecular and intermolecular aldol condensation
Tonis Kanger et al.
JOURNAL OF ORGANIC CHEMISTRY (2007)
In vitro metabolism of gefitinib in human liver microsomes
D Mckillop et al.
XENOBIOTICA (2004)
C2-Symmetric bimorpholines as chiral ligands in the asymmetric hydrogenation of ketones
K Kriis et al.
TETRAHEDRON-ASYMMETRY (2003)
A general synthesis of enantiopure 1,2-aminoalcohols via chiral morpholinones
F Segat-Dioury et al.
TETRAHEDRON (2000)
Share Paper
